Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Operations: 2018-2024

Historic Cash from Operations for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to -$300.9 million.

  • Avidity Biosciences' Cash from Operations fell 138.01% to -$156.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$580.5 million, marking a year-over-year decrease of 214.66%. This contributed to the annual value of -$300.9 million for FY2024, which is 152.70% down from last year.
  • As of FY2024, Avidity Biosciences' Cash from Operations stood at -$300.9 million, which was down 152.70% from -$119.1 million recorded in FY2023.
  • In the past 5 years, Avidity Biosciences' Cash from Operations registered a high of -$37.1 million during FY2020, and its lowest value of -$300.9 million during FY2024.
  • Over the past 3 years, Avidity Biosciences' median Cash from Operations value was -$136.3 million (recorded in 2022), while the average stood at -$185.4 million.
  • Per our database at Business Quant, Avidity Biosciences' Cash from Operations slumped by 1,590.64% in 2020 and then rose by 12.63% in 2023.
  • Yearly analysis of 5 years shows Avidity Biosciences' Cash from Operations stood at -$37.1 million in 2020, then tumbled by 155.44% to -$94.8 million in 2021, then plummeted by 43.72% to -$136.3 million in 2022, then rose by 12.63% to -$119.1 million in 2023, then crashed by 152.70% to -$300.9 million in 2024.